Here we report the results of a pilot study investigating the relative and combined effects of a 12 week course of clozapine and CBT in first-episode psychosis patients with prominent ongoing positive symptoms following their initial treatment. Patients from our early psychosis service who met the inclusion criteria (n = 48) were randomized to one of four treatment groups: clozapine, clozapine plus CBT, thioridazine, or thioridazine plus CBT. The degree of psychopathology and functionality of all participants was measured at baseline then again at 6, 12 and 24 weeks, and the treatment outcomes for each group determined by statistical analysis. A substantial proportion (52%) of those treated with clozapine achieved symptomatic remission, as compared to 35% of those who were treated with thioridazine. Overall, those who received clozapine responded more rapidly to treatment than those receiving the alternative treatments. Interestingly, during the early treatment phase CBT appeared to reduce the intensity of both positive and negative symptoms and thus the time taken to respond to treatment, as well having as a stabilizing effect over time.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420683 | PMC |
http://dx.doi.org/10.1155/2011/394896 | DOI Listing |
Schizophr Bull Open
January 2023
Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, Prestwich, M25 3BL, UK.
Background And Hypothesis: The role of early adversity and trauma is increasingly recognized in psychosis but treatments for trauma and its consequences are lacking. Psychological treatments need to understand the prevalence of these experiences, the relationship with specific symptoms and identify potentially tractable processes that may be targeted in therapy. It was hypothesized that greater adversity, and specifically abuse rather than neglect, would be associated with positive symptoms and specifically hallucinations.
View Article and Find Full Text PDFAm J Nurs
August 2022
Matilda Ryan is a psychiatric mental health nurse practitioner (PMHNP) completing a residency at the Durham Veterans Affairs Medical Center in partnership with Duke University, Durham, NC. Dina Sattenspiel is a PMHNP at Brockton VA Medical Center in Brockton, MA. Alexander Chianese is a resident PMHNP at the Center for Family Guidance in Marlton, NJ, and also runs a dual diagnosis unit at Northbrook Behavioral Health Hospital in Blackwood, NJ. Helen Rice is a PMHNP in private practice at Rittenhouse Psychiatric Associates in Philadelphia. At the time of this research, all were graduate students in the PMHNP program at the University of Pennsylvania School of Nursing in Philadelphia. Contact author: Matilda Ryan, . The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.
Background: Treatment-resistant schizophrenia (TRS) comes with significant medical comorbidities, including heart disease, liver disease, and diabetes-all of which contribute to higher mortality rates and shortened life expectancy. Second-generation antipsychotic medications do not consistently alleviate psychotic symptoms, especially among patients with TRS. Clozapine, the gold standard of pharmacological treatment for TRS, offers only partial relief for many patients.
View Article and Find Full Text PDFMedicina (Kaunas)
November 2020
Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
Treatment resistance is prevalent in early intervention in psychosis services, and causes a significant burden for the individual. A wide range of variables are shown to contribute to treatment resistance in first episode psychosis (FEP). Heterogeneity in illness course and the complex, multidimensional nature of the concept of recovery calls for an evidence base to better inform practice at an individual level.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!